| --- | --- | |----------------------------------------------------------------------|-------| | | | | | | | | | | | | | Targeted Immunotherapies to Improve the Lives of People with Cancer | | | | | | February 2022 Nasdaq: ITOS | | Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements that are not statements of historical fact may be deemed to be forward-loo ...

| --- | --- | --- | |----------------------------------------------------------------------|-------|-------| | | | | | | | | | | | | | | | | | Targeted Immunotherapies to Improve the Lives of People with Cancer | | | | January 2022 Nasdaq: ITOS | | | Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements that are not statements of historical fact may be deeme ...

iTeos Therapeutics Inc. (NASDAQ:ITOS) Q3 2021 Earnings Conference Call November 10, 2021 4:30 PM ET Company Participants Ryan Baker - Head-IR Michel Detheux - President and CEO Matthew Gall - CFO Joe Lager - CMO Conference Call Participants Daina Graybosch - SVB Leerink Anupam Rama - JP Morgan David Nierengarten - Wedbush Securities Swayampakula Ramakanth - H.C. Wainwright Operator Good afternoon and welcome to the iTeos Therapeutics’ Third Quarter 2021 Financial Results Conference Call. This time, all part ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Commission File Number: 001-39401 iTeos Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) ...

iTeos Therapeutics Inc. (NASDAQ:ITOS) Q2 2021 Earnings Conference Call August 12, 2021 8:00 AM ET Company Participants Ryan Baker – Head-Investor Relations Michel Detheux – President and Chief Executive Officer Matthew Gall – Chief Financial Officer Joe Lager – Chief Medical Officer Conference Call Participants Chris Raymond – Piper Sandler Daina Graybosch – SVB Leerink Swayampakula Ramakanth – H.C. Wainwright Anupam Rama – JP Morgan Operator Good morning and welcome to the iTeos Therapeutics’ Second Quarte ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Commission File Number: 001-39401 iTeos Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Dela ...

iTeos Therapeutics, Inc. (NASDAQ:ITOS) Q1 2021 Earnings Conference Call May 13, 2021 4:30 PM ET Company Participants Ryan Baker – Head of Investor Relations Michel Detheux – President and Chief Executive Officer Joe Lager – Chief Medical Officer Matthew Gall – Chief Financial Officer Conference Call Participants Chris Raymond – Piper Sandler Daina Graybosch – SVB Leerink Anupam Rama – JP Morgan Arthur He – HC Wainwright David Nierengarten – Wedbush Securities Operator Good afternoon and welcome to the iTeos ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Commission File Number: 001-39401 iTeos Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Del ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39401 iTeos Therapeutics, Inc. (Exact name of Registrant as specified in its Charter) Delaware 84-3365066 (State or other jurisdicti ...

Pioneering Novel IO Therapies Focused on Key Mechanisms of Immunosuppression March 2021 Disclaimer This Presentation has been prepared by iTeos Therapeutics, Inc. ("we," "us," our "our") and contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations and assumptions rega ...